Baralić Marko, Laušević Mirjana, Ćujić Danica, Bontić Ana, Pavlović Jelena, Brković Voin, Kezić Aleksandra, Mihajlovski Kristina, Hadži Tanović Lara, Assi Milošević Iman, Lukić Jovana, Gnjatović Marija, Todorović Aleksandra, Stojanović Nikola M, Jovanović Dijana, Radović Milan
Faculty of Medicine, University of Belgrade, Doktora Subotića Starijeg 8, 11000 Belgrade, Serbia.
Clinic of Nephrology, University Clinical Centre of Serbia (UCCS), Pasterova 2, 11000 Belgrade, Serbia.
Vaccines (Basel). 2024 Jan 29;12(2):135. doi: 10.3390/vaccines12020135.
The pandemic caused by the SARS-CoV-2 virus had a great impact on the population of patients treated with peritoneal dialysis (PD). This study demonstrates the impact of infection and vaccination in 66 patients treated with PD and their outcomes during a 6-month follow-up. This is the first research that has studied the dynamics of anti-SARS-CoV-2 IgG in serum and effluent. In our research, 57.6% of PD patients were vaccinated, predominantly with Sinopharm (81.6%), which was also the most frequently administered vaccine in the Republic of Serbia at the beginning of immunization. During the monitoring period, the level of anti-SARS-CoV-2 IgG antibodies in the PD patients had an increasing trend in serum. In the group of vaccinated patients with PD, anti-SARS-CoV-2 IgG antibodies had an increasing trend in both serum and effluent, in contrast to non-vaccinated patients, where they decreased in effluent regardless of the trend of increase in serum, but statistical significance was not reached. In contrast to vaccinated (immunized) patients who did not acquire infection, the patients who only underwent the COVID-19 infection, but were not immunized, were more prone to reinfection upon the outbreak of a new viral strain, yet without severe clinical presentation and with no need for hospital treatment.
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒引起的大流行对接受腹膜透析(PD)治疗的患者群体产生了重大影响。本研究展示了66例接受PD治疗的患者中感染和疫苗接种的影响以及他们在6个月随访期间的结果。这是第一项研究血清和腹透液中抗SARS-CoV-2 IgG动态变化的研究。在我们的研究中,57.6%的PD患者接种了疫苗,主要接种的是国药疫苗(81.6%),这也是塞尔维亚共和国免疫接种开始时使用最频繁的疫苗。在监测期间,PD患者血清中抗SARS-CoV-2 IgG抗体水平呈上升趋势。在接种疫苗的PD患者组中,血清和腹透液中的抗SARS-CoV-2 IgG抗体均呈上升趋势,而未接种疫苗的患者,无论血清中抗体呈上升趋势,其腹透液中的抗体均下降,但未达到统计学显著性。与未感染的接种(免疫)患者相比,仅感染过新型冠状病毒肺炎(COVID-19)但未免疫的患者在新毒株爆发时更容易再次感染,但无严重临床表现且无需住院治疗。